At the Myeloma 2015, Dr David Avigan (Beth Israel Deaconess Medical Center, Boston, MA) discusses the development of immune checkpoint inhibitors, including anti-PD-1 antibodies, for the treatment of multiple myeloma (MM). An emerging focus has been on combination therapies and enhancing the anti-MM immune response during treatment using vaccination approaches.
